NSC 361456

Drug Profile

NSC 361456

Alternative Names: Pyrazine diazohydroxide; Pyrazine-2-diazohydroxide; PZDH

Latest Information Update: 16 May 2002

Price : $50

At a glance

  • Originator Unknown
  • Developer Nonindustrial source
  • Class Cytostatics; Pyrazines; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 16 May 2002 Discontinued - Phase-II for Cancer in USA (IV)
  • 25 Aug 1998 A study has been added to the therapeutic trials section
  • 03 Sep 1996 Phase-II clinical trials for Cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top